- Centers & Specialties
- Clinical Interests
- Clinical cardiology
- Nuclear cardiology
- Non-invasive cardiovascular imaging
- Medical Education
- MD, Stanford University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Brigham and Women's Hospital|Fellowship, Massachusetts General Hospital
- Board Certifications
- Cardiovascular Disease
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr Tawakol's research interest is in imaging of atherosclerosis. His work has focused on developing novel diagnostic approaches and novel treatment strategies for atherosclerosis. To that end, Dr Tawakol has developed and validated molecular methods to characterize atherosclerotic plaques, and has made seminal observations validating the use of FDG-PET imaging for the measurement of atherosclerotic plaque inflammation. Currently, he is leading several multi-center trials to evaluate interventions targeting plaque inflammation and is evaluating the potential clinical role of vascular PET imaging for improving the identification of patients at highest risk for atherothrombotic events.
- Research Summary
Multi-modality Imaging of Atherosclerotic Plaques
The majority of myocardial infarctions and sudden cardiac death result from the rupture of plaques which, in most cases, did not cause significant flow limitation prior to the acute event. While stenosis severity (measured with techniques such as angiography and stress testing), is the gold standard for characterization of atherosclerotic disease, it has proven a poor predictor of therapeutic efficacy and a coarse predictor of risk. Novel methods for the characterization of plaques are needed. Accordingly, the focus of Dr Tawako?s laboratory is to develop, validate, and apply novel imaging methods to non-invasively characterize atherosclerotic plaques, with a focus on plaque inflammation.
To that end, Dr Tawakol's group has developed and validated methods using positron emission tomography that enables the non-invasive measurement of plaque inflammation in patients. Currently, Dr Tawakol leads several multi-center trials that are evaluating the efficacy of novel drugs for reducing plaque inflammation.
- Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA, Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119-1121
- Tawakol A, Migrino RQ, Bashian G, Vermylen D, Cury RC, Yates D, Furie K, Bedri S, Houser S, LaMuraglia G, Gewirtz H , Muller JE, Brady TJ, and Fischman AJ . In vivo FDG-PET Imaging Provides a Non-invasive Measure of Carotid Plaque Inflammation in Patients. JACC 2006;48(9):1818-24
- Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, Brady TJ, and Tawakol A. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010 Apr;3(4):388-97.
- Fifer K, Qadir S. Subramanian S, Vijayakumar J, Figueroa AL, Truong Q, Hoffman U, Brady TJ and Tawakol A. Positron Emission Tomography Measurement of Periodontal 18F-Fluorodeoxyglucose Uptake Is Associated With Histologically Determined Carotid Plaque Inflammation. JACC 2011;57 971-976
- Marincheva-Savcheva G , Subramanian S, Qadir S, Figueroa A , Truong Q , Vijayakumar J, Brady TJ, Hoffmann U, Tawakol A. Imaging of the Aortic Valve using 18F-Fluorodeoxyglucose Positron Emission Tomography: Increased Valvular FDG Uptake in Aortic Stenosis. JACC 2011 in press
A biological pathway previously found to contribute to the impact of stress on the risk of cardiovascular disease also may underlie the increased incidence of such disease experienced by individuals with lower socioeconomic status.
Ahmed Tawakol, MD, co-director of the Cardiac MR PET CT Program, discusses the link between stress and atherosclerotic disease, and his team’s work using multimodality imaging to better understand that risk
Landmark Study Identifies Novel Pathway for Translating Emotional Stress into Physical Heart Disease
A team of clinicians led by Ahmed A. Tawakol MD co-director Cardiac MR PET CT Program has found a novel pathway linking psychosocial stress to heart disease.
Statistical analyses of correlated imaging scans and cardiovascular event data shows amygdalar activity significantly associated with arterial inflammation, increased bone-marrow activity and risk of cardiovascular disease events
Mass General physicians presented on the podium moderated sessions or showcased posters over 50 times at the American Heart Association 2017 Scientific Sessions.
For the first time, an MGH study has identified a link between activity in one part of the brain to episodes in the heart.
Mass. General/Mount Sinai-led study connects stress-associated brain activity with cardiovascular risk
A study led by Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai investigators has linked, for the first time in humans, activity in a stress-sensitive structure within the brain to the risk of subsequent cardiovascular disease.
New data showing that high-dose atorvastatin can reduce periodontal inflammation in as little as four weeks suggests a new mechanism of action for statins.
55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-724-3600
Phone 2: 617-726-0791